Vanguard Investments Australia
CRL icon

Vanguard Investments Australia’s Charles River Laboratories CRL Stock Holding History

Vanguard Investments Australia’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.87M Buy
12,660
+44
+0.3% +$7.83K 0.01% 768
2026
Q1 		$2.18M Buy
+12,616
New +$2.34M 0.01% 822

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Investments Australia's CRL Position: Q2 2026 in Review

Vanguard Investments Australia increased its Charles River Laboratories (CRL) stake by 0.35% in Q2 2026, buying an estimated $7.83K and bringing the position to 12,660 shares worth $2.87M. The position accounts for 0.01% of the portfolio, ranked #768.

Vanguard Investments Australia first reported a position in CRL in Q1 2026 and has held it in 2 quarters since. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Vanguard Investments Australia held 12,660 shares of Charles River Laboratories worth $2.87M as of Q2 2026.
  • Vanguard Investments Australia bought 44 Charles River Laboratories shares in Q2 2026, an estimated $7.83K.
  • Charles River Laboratories made up 0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #768 holding.
  • Vanguard Investments Australia first reported a position in Charles River Laboratories in Q1 2026 and has held it in 2 quarters since.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.